2008 - Review: Epoetin and darbepoetin reduce need for blood transfusions but increase risk for thrombosis in patients with cancer

Steensma, David P.
June 2008
ACP Journal Club;6/20/2008, Vol. 148 Issue 4, p6
Academic Journal
The article discusses whether epoetin and darbepoetin are effective and safe for management of anemia in patients with cancer. Research evaluated erythropoietin analogues (EAs)--epoetin (alfa or beta) or darbepoetin alfa. Outcomes included blood transfusion, survival, and thrombosis. Meta-analyses showed that epoetin and darbepoetin groups had fewer transfusions than controls but more thrombotic events.


Related Articles

  • FDA committee recommends restricting use of anti-anaemia drug in cancer. Tanne, Janice Hopkins // BMJ: British Medical Journal (International Edition);3/22/2008, Vol. 336 Issue 7645, p632 

    The article focuses on recommendations which were issued by the U.S. Food and Drug Administration concerning the use of synthetic erythropoietin products in the treatment of anemia in cancer patients. In the recommendations the agency indicated that clinical trials had found an increased risk of...

  • The Two Faces of ESAs: Beneficial or Detrimental? Bryant, Kristy // Drug Formulary Review;Jul2008 Supplement, Vol. 24, special section p1 

    The article analyzes the beneficial and detrimental effects of erythropoietin stimulating agents (ESAs), the current treatment option for chemotherapy-induced anemia (CIA). According to the author, ESA agents have proven to be beneficial and effective in treating CIA in cancer patients. However,...

  • Lineage-Specific Hematopoietic Growth Factors. Kaushansky, Kenneth // New England Journal of Medicine;5/11/2006, Vol. 354 Issue 19, p2034 

    This article discusses the study of hematopoietic cells and growth factor levels which effect lineage-specific cell growth. In a clinical setting the use of hematopoietic growth factors has greatly improved medical response to patients suffering from inadequate blood-cell production. Growth...

  • A paradigm shift for erythropoietin: no longer a specialized growth factor, but rather an all-purpose tissue-protective agent. Savino, R.; Ciliberto, G. // Cell Death & Differentiation;Jul2004 Supplement 1, Vol. 11, pS2 

    Discusses in the shift in the role of erythropoeitin (EPO) from a specialized growth factor to an all-purpose tissue-protective agent. Role of EPO in controlling erythrocyte levels following chronic renal failure or in the supportive care of cancer patients undergoing chemoablative regimens;...

  • Epoetin for Cancer Patients: A Boon or a Danger? Brower, Vicki // JNCI: Journal of the National Cancer Institute;12/17/2003, Vol. 95 Issue 24, p1820 

    The article reports on utility of epoetin for cancer patients. New clinical and basic research with erythropoietin, or epoetin, is raising questions about whether the red blood cell growth factor, often given to cancer patients with chemotherapy-associated anemia and fatigue, might actually...

  • Effects of Recombinant Erythropoietin Therapy on Circulating Endothelial Markers in Hemodialysis Patients. Borawski, Jacek; Mysliwiec, Michal // Clinical & Applied Thrombosis/Hemostasis;Jan2002, Vol. 8 Issue 1, p77 

    Effects of a 4-week course of recombinant human erythropoietin (rHuEpo) therapy on four circulating endothelium-derived cardiovascular risk markers were studied in 20 patients receiving maintenance hemodialysis in relation to surrogates of chronic inflammation, liver function, and arterial blood...

  • Effectiveness of Treating the Renal Anemia in Chronic Hemodialyzed Patients by Epoietin Alpha and Beta. Ostrvica, Edin; Mesic, Enisa; Ostrvica, Dzenana; Delic, Jasmin; Delic-Custendil, Sunita; Hukic, Fatima // Medicinski Arhiv;2010, Vol. 64 Issue 1, p4 

    Introduction: Anemia is an early sign of chronic kidney dysfunction, caused by many different factors, but the insufficient erythropoietin synthesis is the crucial factor in its development. Objectives: The objective of our study was to compare effectiveness of epoietin alpha and beta...

  • Adding IV iron to darbepoetin reduced need for transfusions. Shafer, Emily; Jacob, Harry S. // Hem/Onc Today;5/10/2008, Vol. 9 Issue 8, p54 

    The article reports that according to data from two studies published in the "Journal of Clinical Oncology," supplementing darbepoetin alfa, an erythropoiesis-stimulating agent (ESA), with intravenous (IV) iron improved hematopoietic response rate and reduced treatment failure in patients with...

  • Trends in the Treatment of Anemia Using Recombinant Human Erythropoietin in Patients with HIV Infection. Sullivan, Patrick S.; Hanson, Debra L.; Richardson, James T.; Brooks, John T. // Open AIDS Journal;2011, Vol. 5, p113 

    Background: Treating anemia with erythropoietin (EPO) to hemoglobin (Hb) endpoints >11 g/dL may increase risk of serious adverse cardiovascular events. Methods: We used medical records data (1996-2003 from the Adolescent Spectrum of HIV Disease Project [ASD] and 1996-2006 from the HIV Outpatient...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics